Want to see HK:3692 full AI Analyst Report?
3692 Stock Chart & Stats
HK$31.74
HK$0.06(0.19%)
At close: 4:00 PM EDT
HK$31.74
HK$0.06(0.19%)
Day’s Range― - ―
52-Week RangeHK$28.06 - HK$44.22
Previous CloseN/A
Volume5.79M
Average Volume (3M)11.99M
Market Cap
HK$214.31B
Enterprise ValueHK$143.50K
Total Cash (Recent Filing)HK$37.38B
Total Debt (Recent Filing)HK$4.23B
Price to Earnings (P/E)27.2
Beta0.51
Next Earnings
Mar 30, 2027EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend Yield1.39%
Share Statistics
EPS (TTM)1.10
Shares Outstanding6,064,150,000
10 Day Avg. Volume10,302,170
30 Day Avg. Volume11,988,436
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.73Price Target Upside47.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)1.07
Revenue Forecast (FY)HK$16.98B
Bulls Say, Bears Say
Bulls Say
Re-accelerating Revenue And Strong ProfitabilityRenewed revenue growth combined with exceptionally high gross and net margins indicates strong product economics and commercial execution. This gives Hansoh internal resources to fund research, launches, and lifecycle management while supporting durable earnings power across its pharmaceutical franchises.
Very Conservative Balance SheetMinimal leverage reduces interest and refinancing pressure, leaving the company financially resilient through changes in operating conditions. A large and expanding equity base also preserves flexibility to invest in drug development, commercialization, and strategic opportunities without depending heavily on external borrowing.
Strong Cash Generation And Earnings QualityOperating cash flow exceeding net income provides evidence that reported profits are converting into usable cash rather than remaining mainly accounting earnings. Strong free cash flow supports ongoing R&D, commercial investment, and capital allocation while reducing reliance on debt or equity financing.
Bears Say
Operating Margin VariabilityFluctuating operating margins show that strong gross economics do not consistently translate into stable operating earnings. If this variability persists, it could make profit growth less predictable and constrain management’s ability to plan investment, launches, and other long-term uses of cash.
Volatile Cash ConversionThe wide swing in operating cash flow relative to net income indicates that cash conversion can vary materially between years. Even with strong recent performance, renewed volatility could reduce funding certainty for R&D and commercialization and make internally generated cash less dependable.
Historical Capital-structure VolatilityThe sharp historical movement in leverage suggests that Hansoh’s capital structure has not always been consistent. Although current debt is very low, a future return to higher borrowing could increase financial risk, interest obligations, and constraints on investment during weaker operating periods.
Hansoh Pharmaceutical Group Company Limited News
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$28.06 and its highest was HK$44.22 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$214.31B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Mar 30, 2027 which is in 187 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Aug 26, 2026. The company reported HK$0.819 earnings per share for the quarter, beating the consensus estimate of HK$0.573 by HK$0.246.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Semiannually dividend of HK$0.285 which represents an annual dividend yield of 1.39%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.57.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 6,064,150,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.819 in its last earnings report, beating expectations of HK$0.573. Following the earnings report the stock price went up 0.508%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$46.73 (47.23% Upside)
HK$46.73 (47.23% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.27%
12-Months-Change
Fundamentals
Return on Equity
1.39%
Trailing 12-Months
Asset Growth
40.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
3692 Stock 12 Month Forecast
Average Price Target
HK$46.73
▲(47.23% Upside)
Technical Analysis
HUTCHMED (China)
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―